IDEAYA Biosciences (NASDAQ:IDYA) CAO Sells $382,095.50 in Stock

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total transaction of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock traded down $0.29 on Friday, hitting $36.99. The stock had a trading volume of 677,504 shares, compared to its average volume of 1,373,421. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -23.12 and a beta of -0.09. The stock’s 50 day moving average is $31.50 and its 200-day moving average is $32.63. IDEAYA Biosciences, Inc. has a 52-week low of $21.33 and a 52-week high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same period last year, the firm posted ($0.82) earnings per share. The company’s quarterly revenue was down 39.4% on a year-over-year basis. Equities analysts expect that IDEAYA Biosciences, Inc. will post -4.1 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Guggenheim lifted their target price on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Royal Bank Of Canada reduced their price target on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a report on Tuesday. Truist Financial lowered their price objective on IDEAYA Biosciences from $65.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Wells Fargo & Company lifted their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.25.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its position in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the last quarter. Global Retirement Partners LLC acquired a new position in IDEAYA Biosciences in the fourth quarter worth about $61,000. Comerica Bank increased its holdings in IDEAYA Biosciences by 36.5% in the fourth quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after buying an additional 672 shares during the last quarter. Finally, Fifth Third Bancorp bought a new stake in IDEAYA Biosciences in the first quarter valued at about $84,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.